P3 Health Partners (PIII) Stock Overview
A patient-centered and physician-led population health management company, provides superior care services in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
PIII Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
P3 Health Partners Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.62 |
| 52 Week High | US$16.89 |
| 52 Week Low | US$1.52 |
| Beta | 1.62 |
| 1 Month Change | -13.64% |
| 3 Month Change | 264.39% |
| 1 Year Change | 32.32% |
| 3 Year Change | -91.11% |
| 5 Year Change | -98.05% |
| Change since IPO | -98.01% |
Recent News & Updates
Narrative Update • Jun 26
PIII: Stronger EBITDA And Cleaner Balance Sheet Will Support Further Upside
The analyst fair value estimate for P3 Health Partners has shifted from $10.25 to $14.00, reflecting recent Street price target moves to $14 and analyst commentary pointing to stronger than expected 1Q26 EBITDA, higher full year EBITDA guidance, and a cleaner balance sheet after debt conversion. Analyst Commentary Recent research on P3 Health Partners highlights a mix of optimism around execution in 2026 and lingering caution about how durable the current momentum and valuation reset might be.
Narrative Update • May 22
PIII: Stronger 2026 EBITDA And Balance Sheet Could Support Measured Upside Potential
Analysts have lifted their price target on P3 Health Partners to $14, up from $3, citing stronger than expected 1Q26 adjusted EBITDA, higher full year EBITDA guidance, recent balance sheet improvements, and a higher fair value estimate of $14.0 that reflects updated assumptions for revenue growth, profit margins, and future P/E. Analyst Commentary Bullish analysts are pointing to several factors behind the recent lift in price targets for P3 Health Partners, with a focus on execution in the first quarter of 2026, updated guidance, and balance sheet changes.Recent updates
Narrative Update • Jun 26
PIII: Stronger EBITDA And Cleaner Balance Sheet Will Support Further Upside
The analyst fair value estimate for P3 Health Partners has shifted from $10.25 to $14.00, reflecting recent Street price target moves to $14 and analyst commentary pointing to stronger than expected 1Q26 EBITDA, higher full year EBITDA guidance, and a cleaner balance sheet after debt conversion. Analyst Commentary Recent research on P3 Health Partners highlights a mix of optimism around execution in 2026 and lingering caution about how durable the current momentum and valuation reset might be.Narrative Update • May 22
PIII: Stronger 2026 EBITDA And Balance Sheet Could Support Measured Upside Potential
Analysts have lifted their price target on P3 Health Partners to $14, up from $3, citing stronger than expected 1Q26 adjusted EBITDA, higher full year EBITDA guidance, recent balance sheet improvements, and a higher fair value estimate of $14.0 that reflects updated assumptions for revenue growth, profit margins, and future P/E. Analyst Commentary Bullish analysts are pointing to several factors behind the recent lift in price targets for P3 Health Partners, with a focus on execution in the first quarter of 2026, updated guidance, and balance sheet changes.Narrative Update • Mar 19
PIII: Steady Fair Value View Will Support Constructive Long Term Upside
Analysts have kept their price target for P3 Health Partners steady at $10.25, with a slightly lower discount rate, a modestly adjusted profit margin outlook, and a higher assumed future P/E helping to support the unchanged fair value view. Valuation Changes Fair Value: Unchanged at $10.25, indicating the overall valuation view is steady despite updated inputs.Narrative Update • Mar 05
PIII: Modest Assumption Shifts Will Support Stronger 2026 Upside Potential
Analysts have modestly adjusted their price target for P3 Health Partners to $12.50, reflecting slightly higher projected revenue growth and a small change in expected profit margins, along with a marginally higher forward P/E assumption. Valuation Changes Fair Value: The $12.50 fair value estimate is unchanged, indicating no revision to the overall valuation anchor.Narrative Update • Feb 18
PIII: New ACO Joint Venture Will Support Stronger 2026 Outlook
Analysts have adjusted their price target on P3 Health Partners to $12.50, reflecting updated views on revenue growth, profitability, discount rate, and future P/E assumptions, while keeping their overall fair value estimate steady at $12.50. What's in the News P3 Health Partners and Commonwealth Primary Care ACO formed a joint venture Management Services Organization to support ACO lines of business across Arizona, California, Nevada, Oregon, and North Carolina, with a shared focus on value based care and independent primary care physicians (Key Developments).Narrative Update • Feb 04
PIII: Weaker Q3 aEBITDA Will Set Up Stronger 2026 Outlook
Analysts have reduced their price target on P3 Health Partners from US$20.00 to US$12.50, citing recent aEBITDA results that they viewed as weak, while still noting operational progress they expect to become more evident over time. Analyst Commentary Bullish analysts are taking a longer-term view on P3 Health Partners, even as they acknowledge that recent aEBITDA results have been weak.Narrative Update • Jan 21
PIII: Q3 Setback And Higher Discount Rate May Precede Stronger 2026 Outlook
Narrative Update on P3 Health Partners Analysts have trimmed their price target on P3 Health Partners from US$20.00 to US$12.50, citing recent Q3 aEBITDA results that they view as disappointing, while also noting operational progress that they expect could support a stronger 2026 outlook. Analyst Commentary Bullish analysts are acknowledging the weaker Q3 aEBITDA print but still see enough progress under the surface to support their long term view on P3 Health Partners.Narrative Update • Jan 06
PIII: Operational Progress And New ACO JV Will Support Stronger 2026 Earnings
Analysts recently trimmed their price target on P3 Health Partners to US$12.50 from US$20.00, pointing to weaker than expected Q3 aEBITDA but emphasizing ongoing operational progress that they believe could set up a stronger 2026. Analyst Commentary Bullish Takeaways Bullish analysts view the reduced US$12.50 price target as still supportive of upside potential relative to recent trading levels, reflecting continued confidence in the business model despite weaker Q3 aEBITDA.Narrative Update • Dec 21
PIII: Operational Improvements Will Support Stronger 2026 Earnings Ramp
Narrative Update on P3 Health Partners The analyst price target for P3 Health Partners has been reduced from $20.00 to $12.50 per share, as analysts factor in disappointing Q3 aEBITDA results but acknowledge operational progress that they expect will support a stronger 2026 outlook. Analyst Commentary Analysts have adjusted their views on P3 Health Partners following the recent Q3 aEBITDA shortfall, balancing near term execution concerns with confidence in the company’s longer term trajectory and valuation support.Narrative Update • Dec 07
PIII: Operational Progress And 2026 Earnings Ramp Will Drive Long-Term Upside
Narrative Update on P3 Health Partners The analyst price target for P3 Health Partners has been reduced from $20.00 to $12.50 per share, as analysts cite disappointing recent aEBITDA and growing confidence that operational progress will support a stronger 2026 earnings profile. Analyst Commentary Recent commentary reflects a mixed but generally constructive view on P3 Health Partners, with the lowered price target framed as a recalibration of expectations rather than a loss of confidence in the long term earnings trajectory.Narrative Update • Nov 23
PIII: Margin Expansion And Industry Tailwinds Will Drive Long-Term Upside
Analysts have revised their price target for P3 Health Partners downward from $14.00 to $10.25 per share, citing disappointing recent results. However, they maintain optimism for long-term improvement based on projected growth and margin trends.Narrative Update • Aug 29
Rising Medicare Eligibility And Value-Based Care Will Expand Markets
The notable upward revision in P3 Health Partners’ price target is primarily supported by a significant decline in its forward P/E ratio, indicating improved earnings expectations, with the fair value estimate increased from $8.00 to $14.00. What's in the News P3 Health Partners raised earnings guidance, projecting total revenues between $1.35 billion and $1.5 billion for fiscal 2025.
New Narrative • Apr 09
US Healthcare Operational Improvements Will Pave Path To Profitability
Strategic initiatives in operational efficiencies, contracting, and execution aim to significantly boost EBITDA, net margins, and earnings.Analysis Article • Nov 20
Some P3 Health Partners Inc. (NASDAQ:PIII) Analysts Just Made A Major Cut To Next Year's Estimates
One thing we could say about the analysts on P3 Health Partners Inc. ( NASDAQ:PIII ) - they aren't optimistic, having...Analysis Article • Aug 26
Health Check: How Prudently Does P3 Health Partners (NASDAQ:PIII) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jun 07
P3 Health Partners: Moving In The Right Direction In 2024
Summary P3 Health Partners is collaborating with healthcare providers in five states, providing assistance for compensation. The company's revenue has been steadily growing, but has not yet been profitable. However, profitability is expected in 2024. The recent announcement of a new CEO may bring renewed attention to PIII stock. Read the full article on Seeking AlphaShareholder Returns
| PIII | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -11.1% | -0.1% | -2.0% |
| 1Y | 32.3% | 40.3% | 15.1% |
Return vs Industry: PIII underperformed the US Healthcare industry which returned 40.3% over the past year.
Return vs Market: PIII exceeded the US Market which returned 15.1% over the past year.
Price Volatility
| PIII volatility | |
|---|---|
| PIII Average Weekly Movement | 55.6% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PIII's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PIII's weekly volatility has increased from 31% to 56% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 320 | Aric Coffman | p3hp.org |
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company was founded in 2020 and is based in Henderson, Nevada.
P3 Health Partners Inc. Fundamentals Summary
| PIII fundamental statistics | |
|---|---|
| Market cap | US$67.45m |
| Earnings (TTM) | -US$126.24m |
| Revenue (TTM) | US$1.47b |
0.0x
P/S Ratio-0.3x
P/E RatioIs PIII overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PIII income statement (TTM) | |
|---|---|
| Revenue | US$1.47b |
| Cost of Revenue | US$1.48b |
| Gross Profit | -US$10.98m |
| Other Expenses | US$115.27m |
| Earnings | -US$126.24m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 10, 2026
| Earnings per share (EPS) | -37.96 |
| Gross Margin | -0.75% |
| Net Profit Margin | -8.58% |
| Debt/Equity Ratio | -234.2% |
How did PIII perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/24 00:10 |
| End of Day Share Price | 2026/07/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
P3 Health Partners Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Haynor | Lake Street Capital Markets, LLC |
| Ryan Langston | TD Cowen |